Merck & Company, Inc. (NYSE:MRK) Updates FY17 Earnings Guidance

Merck & Company, Inc. (NYSE:MRK) updated its FY17 earnings guidance on Friday. The company provided EPS guidance of $3.91-3.97 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.88. The company issued revenue guidance of $40.0-40.5 billion, compared to the consensus revenue estimate of $40.34 billion.

Several brokerages have commented on MRK. J P Morgan Chase & Co set a $70.00 price target on Merck & and gave the stock a buy rating in a research report on Sunday, October 29th. Berenberg Bank reaffirmed a hold rating on shares of Merck & in a research report on Wednesday, November 1st. BMO Capital Markets set a $70.00 price target on Merck & and gave the stock a buy rating in a research report on Wednesday, October 18th. Zacks Investment Research downgraded Merck & from a hold rating to a sell rating in a research report on Wednesday, October 11th. Finally, Credit Suisse Group restated an outperform rating and set a $74.00 price objective (down from $75.00) on shares of Merck & in a research report on Tuesday, September 5th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $67.07.

Shares of Merck & Company, Inc. (NYSE MRK) traded down $0.73 during trading on Friday, hitting $55.48. The company’s stock had a trading volume of 16,743,801 shares, compared to its average volume of 9,494,131. Merck & Company, Inc. has a 12 month low of $54.41 and a 12 month high of $66.80. The company has a market capitalization of $153,140.61, a P/E ratio of 14.45, a P/E/G ratio of 2.42 and a beta of 0.78. The company has a quick ratio of 1.21, a current ratio of 1.43 and a debt-to-equity ratio of 0.57.

Merck & (NYSE:MRK) last announced its quarterly earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The company had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. During the same period in the prior year, the company earned $1.07 earnings per share. The company’s revenue for the quarter was down 2.0% compared to the same quarter last year. equities research analysts expect that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.

In related news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total transaction of $281,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.25% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Merck & Company, Inc. (NYSE:MRK) Updates FY17 Earnings Guidance” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/11/11/merck-company-inc-mrk-updates-fy17-earnings-guidance.html.

Large investors have recently bought and sold shares of the stock. Krilogy Financial LLC boosted its position in Merck & by 0.4% during the second quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock valued at $201,000 after purchasing an additional 11 shares during the last quarter. Balentine LLC boosted its position in Merck & by 1.0% during the second quarter. Balentine LLC now owns 2,107 shares of the company’s stock valued at $135,000 after purchasing an additional 20 shares during the last quarter. Thompson Davis & CO. Inc. boosted its position in Merck & by 0.9% during the second quarter. Thompson Davis & CO. Inc. now owns 4,313 shares of the company’s stock valued at $276,000 after purchasing an additional 40 shares during the last quarter. Southeast Asset Advisors Inc. boosted its position in Merck & by 2.0% during the second quarter. Southeast Asset Advisors Inc. now owns 5,428 shares of the company’s stock valued at $348,000 after purchasing an additional 105 shares during the last quarter. Finally, Coastline Trust Co boosted its position in Merck & by 0.3% during the second quarter. Coastline Trust Co now owns 57,399 shares of the company’s stock valued at $3,679,000 after purchasing an additional 150 shares during the last quarter. Institutional investors and hedge funds own 72.84% of the company’s stock.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Earnings History and Estimates for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply